



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2019/031166

(22) International Filing Date:

07 May 2019 (07.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/668,088	07 May 2018 (07.05.2018)	US
62/753,725	31 October 2018 (31.10.2018)	US

(71) Applicants: **GENMAB A/S** [DK/DK]; Kalvebod Brygge 43, DK-1560 Copenhagen V (DK). **MERCK SHARP & DOHME CORP.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **MSD INTERNATIONAL GMBH** [CH/CH]; Weysstrasse 20, 6000 Luzern 6 (CH).

(72) Inventors: **RANGWALA, Reshma Abdulla**; c/o Genmab US, Inc., 902 Carnegie Center, Suite 301, Princeton, New Jersey 08540 (US). **BREIJ, Esther C.W.**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **VERPLOEGEN, Sandra**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT

Utrecht (NL). **ABIDOYE, Oyewale O.**; c/o Seattle Genetics, Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US). **NICACIO, Leonardo Viana**; c/o Seattle Genetics, Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US). **CAO, Anthony**; c/o Seattle Genetics, Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US). **GARDAI, Shyra**; c/o Seattle Genetics, Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US).


(74) Agent: **BANKO, Max** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE

FIG. 4B



(57) Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))